Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/35769
Title: | Integrative molecular analysis of colorectal cancer and gastric cancer: What have we learnt?. | Authors: | Athauda A.;Segelov E. ;Ali Z.;Chau I. | Monash Health Department(s): | Oncology | Institution: | (Athauda, Ali, Chau) Gastrointestinal and Lymphoma Unit, The Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom (Segelov) Monash Health and Monash University, Level 7, MHTP Building, Monash Health 246 Clayton Road, Victoria 3168, Australia | Issue Date: | 3-Jan-2019 | Copyright year: | 2019 | Publisher: | W.B. Saunders Ltd | Place of publication: | United Kingdom | Publication information: | Cancer Treatment Reviews. 73 (pp 31-40), 2019. Date of Publication: February 2019. | Journal: | Cancer Treatment Reviews | Abstract: | Gastrointestinal (GI) malignancies comprise a diverse group of cancers with varying aetiology, clinical course, management and prognosis. Advances over the last decade in molecular diagnostics in colorectal cancer (CRC) have helped to improve our understanding of the underlying complex mechanisms in the development and progression of this highly heterogenous disease. Large scale integrative analysis has identified molecularly distinct subgroups of CRC with differing clinical behaviour. It was hoped that these discoveries would fuel the development of novel drug targets and new treatments to shift the management of advanced CRC from an empirical strategy to a biomarker driven approach based on underlying molecular characteristics. However, biomarkers in current clinical practice remain limited in CRC. Gastric cancer (GC) has also been slow to benefit from biomarker discovery and development and the successful utilisation of targeted therapies, with the exception of trastuzumab in HER2 positive cancers. More recently, molecular analysis of GC has also identified distinct subgroups within these cancers with differing behaviour and therapeutic targets. In addition, our deeper understanding of the underlying molecular biology of GI cancers has led to the consideration of alterations above and beyond gene mutations. The clonal, stromal and immune characteristics of GI malignancies are increasingly recognised as important in therapeutic targeting. The challenge remains to apply the data generated through molecular exploration into clinical practice in order to provide personalised treatment to each individual patient.Copyright © 2018 Elsevier Ltd | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1016/j.ctrv.2018.12.004 | PubMed URL: | 30597479 [http://www.ncbi.nlm.nih.gov/pubmed/?term=30597479] | ISSN: | 0305-7372 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/35769 | Type: | Review | Subjects: | genetic parameters human microsatellite instability *molecular diagnosis oncogene oncogene K ras oncogene N ras personalized medicine prediction review *stomach cancer/di [Diagnosis] *stomach cancer/dt [Drug Therapy] *stomach cancer/et [Etiology] tumor suppressor gene bevacizumab/dt [Drug Therapy] biological marker/ec [Endogenous Compound] cetuximab/dt [Drug Therapy] fluorouracil/dt [Drug Therapy] irinotecan/dt [Drug Therapy] messenger RNA/ec [Endogenous Compound] pembrolizumab/dt [Drug Therapy] ramucirumab/dt [Drug Therapy] trastuzumab/dt [Drug Therapy] vemurafenib/dt [Drug Therapy] microsatellite stability PTEN gene TP53 gene *colorectal cancer/di [Diagnosis] cancer chemotherapy cancer classification cancer immunotherapy cancer patient cancer prognosis cancer survival cancer therapy carcinogenesis clinical practice *colorectal cancer/dt [Drug Therapy] *colorectal cancer/et [Etiology] disease association drug research epithelial mesenchymal transition gene expression gene expression profiling disease association drug research epithelial mesenchymal transition gene expression gene expression profiling genetic parameters human microsatellite instability *molecular diagnosis oncogene oncogene K ras oncogene N ras personalized medicine prediction Review *stomach cancer / *diagnosis / *drug therapy / *etiology cancer chemotherapy tumor suppressor gene cancer classification cancer immunotherapy cancer patient cancer prognosis cancer survival cancer therapy carcinogenesis clinical practice *colorectal cancer / *diagnosis / *drug therapy / *etiology |
Type of Clinical Study or Trial: | Review article (e.g. literature review, narrative review) |
Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.